ReviewWorld journal of gastroenterology2014
Eradication of Helicobacter pylori infection: which regimen first?
Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Comparison of vonoprazan-based with rabeprazole-based dual therapy for treatment-naive patients of Helicobacter pylori infection: a prospective, multi-center, randomized controlled study.Journal of gastroenterology · 2023Trial
- Can the treatment duration be shortened in bismuth-containing therapies for Helicobacter pylori eradication?The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019Trial
- Trial
- A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.Medicine · 2015Trial
- The effects of probiotics on treatment of Helicobacter pylori eradication in children.Saudi medical journal · 2015Trial
- Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial.Global journal of health science · 2014Trial
- A comparative study of the effect of 10-day esomeprazole containing levofloxacin versus clarithromycin sequential regimens on the treatment of Iranian patients withIndian journal of pharmacologyTrial
- Helicobacter pylori eradication in the face of escalating anti-microbial resistance: Geographic heterogeneity and emerging treatment strategies.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Review
- Eradication rates of Helicobacter pylori regimens and predictors of treatment failure: A multicenter real-world study in Saudi Arabia.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026Article
- Update on the pathogenesis and clinical management ofWorld journal of gastrointestinal pathophysiology · 2025Review
- Comparative Efficacy of Triple Versus Quadruple Therapy for the Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication ofFrontiers in pharmacology · 2025Article
- Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.United European gastroenterology journal · 2024Article
- A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance.Internal medicine (Tokyo, Japan) · 2023Article
- The Importance of Accurate Early Diagnosis and Eradication inAntibiotics (Basel, Switzerland) · 2022Review
- Extra-Gastric Manifestations ofJournal of clinical medicine · 2020Review
- Pathogenesis and clinical management ofWorld journal of gastroenterology · 2019Review
- Prevalence and Risk Factors ofJournal of tropical medicine · 2019Article
- Clarithromycin-Susceptible But VirulentInfection and drug resistance · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) is a well-known human pathogen that plays an essential role in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric malignancies. Although H. pylori is susceptible to several antimicrobials, this infection has proven challenging to cure because of the increasing prevalence of bacterial strains that are resistant to the most commonly used antimicrobials, particularly clarithromycin. An effective (i.e., > 90%) first-line therapy is mandatory for avoiding supplementary treatments and testing, and more importantly for preventing the development of secondary resistance. This study reviews the recent literature on first-line therapies for H. pylori. The eradication rates following standard triple therapy (a proton pump inhibitor plus amoxicillin and clarithromycin) for H. pylori infection are declining worldwide. Several first-line strategies have been proposed to increase the eradication rate, including extending the treatment duration to 14 d, the use of a four-drug regimen (bismuth-containing quadruple, sequential, and concomitant treatments), and the use of novel antibiotics, such as fluoroquinolones. However, the efficacy of these regimens is controversial. A first-line eradication regimen should be based on what works best in a defined geographical area and must take into account the prevalence of antimicrobial resistance in that region.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.